Key Highlights:
- NovoBiome will develop breakthrough LBPs targeting the microbiome-gut-liver axis
- The company has already developed its first drug candidate for hepatic conditions like NASH and NAFLD
- The company is also developing a platform to replicate human intestinal anatomy to gain more insights into disease physiopathology
NovoBiome’s ADC-001 aims for human trials around 2022-23
A majority of people around the world suffer from serious liver problems like Hepatitis A, Hepatitis B, Hepatitis C. About 2 million people die due to liver issues caused by liver complications like cirrhosis and due to viral hepatitis and hepatocellular carcinoma. As per statistics, Cirrhosis stands as the 11th most common cause of death in the entire world. Various factors like alcohol usage, obesity, toxic lifestyles, unhealthy diet contribute to the deterioration of liver in the long run. In order to maintain liver health, one needs to focus on adapting to healthy diet and lifestyle.
Likewise, metabolic disorders also result in liver complications. Due to the growing epidemic of metabolic disorders instigated by unhealthy lifestyles, several people are suffering from complex liver problems like NASH (Nonalcoholic Steato-Hepatitis), NAFLD (Non-Alcoholic Fatty Liver Disease), etc. The number of people suffering from NASH is increasing rapidly around the world. According to reports, the NASH market is rising rapidly and is expected to reach $18.3 billion by 2026 in the US and Europe’s 5 largest markets, a CAGR of 63% from 20162. Focusing on the critical nexus of the liver, a French drug developing company has successfully been launched to develop breakthrough drugs for complicated liver diseases.
The NovoBiome Company
The NovoBiome company is a France based drug discovery company that has been established by a team of globally acclaimed experts in the field of Microbiology and Artificial Intelligence. The company was launched on 4 May, 2021 and will develop breakthrough Live Biotherapeutics Products (LBPs)1 targeting the microbiome-gut-liver axis.
NovoBiome was established with the primary motto to develop breakthrough liver-oriented products that would target the microbiome-gut-liver axis. It was co-founded by world leading experts in the fields of Microbiome research and AI and is led by Pierre Pierre-Yves Mousset, Chief Executive Officer; Hervé Blottière, Chief Scientific Officer; Olivier Tastet, Chief AI Officer; and Joël Doré, Senior Scientific Consultant. According to the official website of the drug developing company, “NovoBiome is building a comprehensive, disruptive ex-vivo research and discovery platform to analyze the symbiotic relationship between the microbiota and the human intestine.”
NovoBiome’s first drug candidate
The France based company has already developed its first drug candidate for hepatic conditions like NAFLD and NASH. NAFLD is counted amongst one of the most common causes that leads to chronic liver diseases. NAFLD is a condition where excess fat is stored in the liver. It can further lead to NASH which is a further serious liver condition, with the added presence of hepatitis and liver damage.
Since NovoBiome specializes in developing LBPs, its first drug candidate is ADC-001. According to reports, ADC-001 targets the potential therapies for hepatic conditions like NAFLD and NASH. The NASH market is considered as the third wave in metabolic diseases, after the surge in obesity and Type 2 Diabetes. ADC-001 consists of an anti-inflammatory bacterium, a member of the class Coriobacteriia. This bacterium possesses strong therapeutic effects in vitro and in animal models. The ADC-001 is said to currently be under development with the aim of undertaking human trials by the year 2022-23.
NovoBiome is also developing an ex-vivo research and discovery platform by the name NovoSift. This platform is designed to replicate the human intestinal physiology to gain new insights into learning disease pathophysiology, novel drug tests, compounds and LBP drug candidates.
Also Read: Google Doodle fostering to wear the mask and get vaccinated
